<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608903</url>
  </required_header>
  <id_info>
    <org_study_id>DeniseMafra11</org_study_id>
    <nct_id>NCT04608903</nct_id>
  </id_info>
  <brief_title>Effects of Sulforaphane for Patients With Chronic Kidney Disease</brief_title>
  <official_title>Salutary Effects of Sulforaphane for Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal Fluminense</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal Fluminense</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Chronic Kidney Disease (CKD) have many complications associated with&#xD;
      inflammation, oxidative stress and intestinal dysbiosis, which are closely related to the&#xD;
      progression of kidney failure and cardiovascular disease. Sulforaphane, an isothiocyanate&#xD;
      found in cruciferous vegetables (Family: Brassicaceae) is recognized as one of the most&#xD;
      important activators of erythroid nuclear factor 2 related to factor 2 (Nrf2). However,&#xD;
      clinical evidence to assess the effects of sulforaphane in patients with CKD is scarce, and&#xD;
      there are no studies that have investigated its effects on the expression of genes and&#xD;
      markers related to inflammation in these patients. Thus, the present project proposes a&#xD;
      longitudinal study of the clinical trial type that aims to evaluate the effects of&#xD;
      sulforaphane on transcription factors and inflammatory markers in patients with CKD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a longitudinal, randomized, crossover study with patients with CKD on hemodialysis&#xD;
      and in non-dialysis patients.&#xD;
&#xD;
      Both groups will receive 4g of sulforaphane per day for 2 months and the placebo group will&#xD;
      receive 4g of corn starch colored with chlorophyll for 2 months. Peripheral blood mononuclear&#xD;
      cells (PBMC) are being isolated for expression of Nrf2, NF-kB, and NADPH quinone&#xD;
      oxidoreductase 1 (NQO1), HO-1, VCAM-1, E-selectin, NLRP3, IL-1B, IL 18, PGC1-α, Sestrina,&#xD;
      NRF2, NRF-1 e TFAM mRNA expression by a quantitative real-time polymerase chain reaction.&#xD;
      Antioxidant enzymes activity (catalase-CAT and glutathione peroxidase-GPx), high-sensitivity&#xD;
      C-reactive protein (hs-CRP) will be assessed using an enzyme-linked immunosorbent assay&#xD;
      (ELISA).The serum concentration of other cytokines and growth factors will be detected by&#xD;
      means of a multiparametric immunoassay based on magnetic microspheres marked with XMap&#xD;
      (Luminex Corp, USA) before and after supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Sulforaphane group or Placebo group. Thus, 52 participants with CKD under conservative treatment will be recruited at the Renal Nutrition Clinic of UFF and 70 patients under regular HD treatment</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antioxidant and anti-inflammatory biomarker</measure>
    <time_frame>6 months</time_frame>
    <description>Get blood samples to evaluate the supplementation effects in antioxidant and anti-inflammatory biomarker- nuclear receptor factor 2 (Nrf2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory biomarker</measure>
    <time_frame>6 months</time_frame>
    <description>Get blood samples to evaluate the supplementation effects in inflammatory biomarker- factor nuclear kappa B (NFkB)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uremic toxins</measure>
    <time_frame>6 months</time_frame>
    <description>Get blood samples to evaluate the supplementation effects on uremic toxins plasma levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Sulforaphane Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 4g L-Sulforaphane per day, for 2 months and after the washout period (2 months) the groups will be crossed and will receive the same amount of placebo as the other group for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of 4g of corn starch colored with chlorophyll, per day, for 2 months and then after the washout period (2 months) the groups will be crossed and will receive the same amount of sulfarophane as the treatment group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-sulforaphane 1%</intervention_name>
    <description>Administration of 4g L-Sulforaphane per day, for 2 months</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>Sulforaphane Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Group</intervention_name>
    <description>Administration of 4g corn starch colored with chlorophyll, per day, for 2 months</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>Sulforaphane Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 75 years&#xD;
&#xD;
          -  Clinical diagnosis of Chronic Kidney Disease&#xD;
&#xD;
          -  Conservative treatment group: CKD stages 3 and 5 receiving nutritional treatment for&#xD;
             at least 6 months&#xD;
&#xD;
          -  Hemodialysis group: Hemodialysis patients for more than 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients pregnant&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Using antibiotics in the last 3 months&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Clinical diagnosis of infectious diseases&#xD;
&#xD;
          -  Clinical diagnosis of Cancer&#xD;
&#xD;
          -  Clinical diagnosis of AIDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Denise Mafra, Phd</last_name>
    <phone>+55 21 985683003</phone>
    <email>dmafra30@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Denise Mafra</name>
      <address>
        <city>Niterói</city>
        <state>Rio De Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Cardozo LFMF, Alvarenga LA, Ribeiro M, Dai L, Shiels PG, Stenvinkel P, Lindholm B, Mafra D. Cruciferous vegetables: rationale for exploring potential salutary effects of sulforaphane-rich foods in patients with chronic kidney disease. Nutr Rev. 2021 Oct 11;79(11):1204-1224. doi: 10.1093/nutrit/nuaa129.</citation>
    <PMID>33338213</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforaphane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

